About agenus - AGEN
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.
AGEN At a Glance
Agenus, Inc.
3 Forbes Road
Lexington, Massachusetts 02421-7305
| Phone | 1-781-674-4400 | Revenue | 103.46M | |
| Industry | Biotechnology | Net Income | -227,212,000.00 | |
| Sector | Health Technology | Employees | 316 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
AGEN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.569 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.228 |
| Enterprise Value to Sales | 4.54 |
| Total Debt to Enterprise Value | 0.918 |
AGEN Efficiency
| Revenue/Employee | 327,414.557 |
| Income Per Employee | -719,025.316 |
| Receivables Turnover | 254.209 |
| Total Asset Turnover | 0.383 |
AGEN Liquidity
| Current Ratio | 0.206 |
| Quick Ratio | 0.206 |
| Cash Ratio | 0.183 |
AGEN Profitability
| Gross Margin | 86.634 |
| Operating Margin | -120.264 |
| Pretax Margin | -224.497 |
| Net Margin | -219.607 |
| Return on Assets | -84.124 |
| Return on Equity | N/A |
| Return on Total Capital | -216.45 |
| Return on Invested Capital | -1,660.239 |
AGEN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 410.921 |
| Total Debt to Total Assets | 190.635 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 294.867 |